Nevada’s legal cannabis market runs in plain sight, yet unlicensed sales keep pace because the rules still leave openings. Price gaps, compliance costs, patchy access, and limited places to consume make the illicit channel feel easier for many buyers. This feature tracks what the numbers show, why raids only disrupt, and what actually shrinks underground sales.
Why Black People Still Pay More for Weed
Cannabis use rates are similar across races, but arrests are not. Black Americans are still arrested for marijuana possession at several times the rate of white Americans, even as legalization spreads. This investigation breaks down the data, the role of possession-only enforcement, and why legalization without repair keeps old lines firmly in place.
THE CANNABIS LIE: Vol. 1
This new investigative series begins by confronting one of cannabis policy’s most durable myths. THC percentage became a convenient shortcut for harsher laws, even though higher potency has never equaled higher danger. Vol. 1 documents how numbers replaced evidence and how courts, media, and policy still punish people for a claim that cannot survive scrutiny.
The Drug Test Lie Finally Cracks in New Mexico
New Mexico’s Senate Bill 129 challenges the long standing assumption that a positive cannabis test equals impairment. By separating outdated drug testing from actual workplace safety, the bill aims to protect medical cannabis patients from job discrimination while preserving employer authority over real on the job risk and misconduct.
How Cannabis Can Cost You Your Gun
Federal law still allows cannabis use to strip Americans of firearm rights without proof of danger or misuse. As the Supreme Court weighs United States v. Hemani, courts are confronting whether the government can continue punishing people based on status rather than conduct in a country where cannabis is legal in most states.
Reefer Report Card Vol. 32: Kicking the Can Again
This week’s Reefer Report Card tracks a familiar pattern in cannabis policy: delay dressed as progress. Federal lawmakers punted again on hemp regulation, states flirted with dismantling legal markets, and patients were left waiting. Oversight weakened, accountability faded, and reform stalled. Another week in weed, graded.